Phytoradiotherapy to enhance cancer treatment outcomes with cannabidiol, bitter melon juice, and plant hemoglobin.
anemia
bitter melon juice (BMJ)
cannabidiol (CBD)
pancreatic adenocarcinoma
phytomedicines
phytoradiotherapy
plant hemoglobin
radiotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
10
2022
accepted:
02
12
2022
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
Despite technological advances in radiation therapy for cancer treatment, many patient populations still experience mediocre survival percentages, local control, and quality of life. Additionally, much of the world lacks access to expensive, modern treatment options. The need for innovative, cost-effective solutions that can improve patient treatment outcomes is essential. Phytomedicines have been shown to induce apoptotic tumor cell death, diminish tumor progression, reduce cancer incidence, alleviate harmful hypoxic conditions, and more. While an ample amount of research is available that characterizes many phytomedicines as having anti-cancer properties that increase tumor cell killing/control and mitigate the harmful side effects of radiation damage, little work has been done to investigate the synergistic effect of phytoradiotherapy: combining radiation treatment with phytomedicines. In this study, a protocol for testing the radiosensitizing effects of phytomedicines was validated and used to investigate the well-known plant based medicine cannabidiol (CBD) and the lesser-known medicinal fruit Bitter Melon. Additionally, based on its high concentration of plant hemoglobin which has been shown to abate hypoxia, the African-indigenous
Identifiants
pubmed: 36776362
doi: 10.3389/fonc.2022.1085686
pmc: PMC9909600
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1085686Informations de copyright
Copyright © 2023 Alfonzetti, Moreau, Yasmin-Karim, Ngwa, Avery and Goia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Phys Med Biol. 2018 Dec 19;64(1):01TR01
pubmed: 30523903
Infect Disord Drug Targets. 2021;21(3):328-338
pubmed: 32568024
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):624-637
pubmed: 28126309
J Patient Exp. 2017 Sep;4(3):108-113
pubmed: 28959715
Z Lebensm Unters Forsch. 1993 Apr;196(4):329-38
pubmed: 8493816
J Pharmacol Exp Ther. 2004 Mar;308(3):838-45
pubmed: 14617682
Methods Mol Med. 2005;110:21-8
pubmed: 15901923
J Biomed Biotechnol. 2012;2012:769896
pubmed: 22131823
Nat Rev Mol Cell Biol. 2016 Feb;17(2):65
pubmed: 26695192
Br J Radiol. 2017 Jan;90(1069):20160474
pubmed: 27416998
Trends Pharmacol Sci. 2012 Apr;33(4):207-14
pubmed: 22398146
Nanomaterials (Basel). 2020 Nov 13;10(11):
pubmed: 33202903
Oncotarget. 2017 Aug 3;8(39):66226-66236
pubmed: 29029506
J Pathol. 2019 Jun;248(2):131-141
pubmed: 30838636
Cancers (Basel). 2020 Oct 30;12(11):
pubmed: 33143283
Mayo Clin Proc. 2012 Oct;87(10):935-43
pubmed: 23036669
Bosn J Basic Med Sci. 2019 Feb 12;19(1):14-23
pubmed: 30172249
Front Oncol. 2021 Feb 08;10:624663
pubmed: 33628736
Curr Oncol. 2016 Mar;23(2):S23-32
pubmed: 27022311
Front Oncol. 2019 Jul 23;9:660
pubmed: 31396485
Phys Med Biol. 1973 Jan;18(1):78-87
pubmed: 4803965
Carcinogenesis. 2013 Jul;34(7):1585-92
pubmed: 23475945
Curr Oncol. 2016 Aug;23(4):e392-408
pubmed: 27536189
Front Oncol. 2018 Apr 24;8:114
pubmed: 29740535
Molecules. 2020 Jan 25;25(3):
pubmed: 31991819